학술논문
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
Document Type
Article
Author
Mosenzon, Ofri; Blicher, Thalia Marie; Rosenlund, Signe; Eriksson, Jan W; Heller, Simon; Hels, Ole Holm; Pratley, Richard; Sathyapalan, Thozhukat; Desouza, Cyrus; Abramof, R; Alpenidze, D; Aronoff, S; Astamirova, K; Barker, B; Bedel, G; Belousova, L; Benson, M; Beshay, I; Biggs, W; Blaze, K; Bogdanski, P; Busch, R; Chaidarun, S; Chandran, S; Chang, A; Chilka, S; Cleland, A; Connery, L; Cornett, G; Delgado, B; Desouza, C; Donner, T; Eliasson, K; Eriksson, J; Folkerth, S; Forshaw, K; Frandsen, H A; Frolova, E; Gandy, W; Gatipon, G; Golovach, A; Gonzalez-Orozco, L; Gumprecht, J; Haddad, E; Hansen, T K; Hart, T; Hasan, S; Hella, B; Heller, S; Hellgren, M; Hewitt, M; Hietaniemi, S; Hitz, M; Houser, P; Huntley, R; Jackson, R; Jakobsen, P E; Kapoor, A; Kargina, L; Kazakova, E; Khan, K; Klein, E; Knoble, H; Krasnopeeva (Kabachkova), N; Krzeminski, A; Kunitsyna, M; Lawhead, J; Levin, K; Levin, P; Lewy-Alterbaum, L; Lindmark, S; Lindsay, R; Luts, A; Lysenko, T; Madsbad, S; Maxwell, T; Mbogua, C; Mcknight, J; Metsärinne, K; Milovanova, T; Morawski, E; Mosenzon, O; Nabriski, D; Nguyen, H; Nicol, P; Nieminen, S; Nikkola, A; Norwood, P; O'Donnell, P; Odugbesan, A; Parker, J; Pergaeva, Y; Peskov, A; Plevin, S; Pouzar, J; Pratley, R; Reed, J; Rossing, P; Sathyapalan, T; Sergeeva-Kondrachenko, M; Shaikh, Z; Shamkhalova, M; Shehadeh, N; Shlesinger, Y; Silver, R; Snyder, B; Soufer, J; Strand, J; Sulosaari, S; Tirosh, A; Traylor, H; Uhlenius, N; Vagapova, G; Yanovskaya, M; Zarutskaya, L; Zhdanova, E
Source
The Lancet Diabetes & Endocrinology; July 2019, Vol. 7 Issue: 7 p515-527, 13p
Subject
Language
ISSN
22138587; 22138595
Abstract
Oral semaglutide is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly associated with renal impairment, restricting treatment options. We aimed to investigate the efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment.